Fleshing out understanding of Covid-19, this program looks at the interrelationship between elements of the military, big pharma, therapeutic measures selected for early deployment against the “Plandemic” and the full-court press underway against China.
Specifically, we wonder if the DARPA research into bat-borne coronaviruses and the apparent dissemination of Covid-19 as part of the covert operations constellation being directed against China may have driven development of those therapeutic measures.
In March of this year, the Pentagon secured remdesivir for treating U.S. service personnel. In FTR #1138, we looked at remdesivir being tested on rhesus macaques in March of 2019. In August of last year, the CDC closed down the United States Army Medical Institute of Infectious Diseases, in part because of deficient handling of waste produced by “non-human” primates infected with an unnamed “select agent.”
Was that “select agent” Ebola? A bat-borne coronavirus? SARS CoV-2?
Remdesivir was definitely being tested on MERS at a facility in Montana that was a base for Willy Burgdorfer’s biological warfare research resulting the development of Lyme Disease.
The MERS virus was also a focal point for testing of the messenger RNA vaccines being developed (largely under DARPA auspices). That testing appears to have been a factor in fast-tracking the Moderna vaccine for SARS CoV-2 (see below).
Next, we review elements of a thought-provoking and disturbing article about DARPA research into bat-borne diseases, including some caused by coronaviruses.
As readers digest this information, remember that DARPA can bring to bear the twined technologies artificial intelligence and super-computers. It has the state of the art with respect to both. Combined with gene editing, that technological pairing offers the possibility of truly horrifying synthetic viruses.
Whitney Webb has provided us with troubling insight into Pentagon research–some of which remains classified, including:
1.–DARPA’s study of “gene-driving technology”–” . . . . Concerns about Pentagon experiments with biological weapons have garnered renewed media attention, particularly after it was revealed in 2017 that DARPA was the top funder of the controversial ‘gene drive’ technology, which has the power to permanently alter the genetics of entire populations while targeting others for extinction. . . .”
2.–DARPA’s funding of Moderna’s mRNA vaccine technology.
3.–The closure of the USAMRIID:” . . . . The U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) facility at Fort Detrick, Maryland — the U.S. military’s lead laboratory for ‘biological defense’ research since the late 1960s — was forced to halt all research it was conducting with a series of deadly pathogens . . . . USAMRIID has recently been involved in research born out of the Pentagon’s recent concern about the use of bats as bioweapons. . . .”
Moderna’s SARS-CoV-2 vaccine continues to generate controversy. Despite receiving funding from DARPA, no mention of the government backing was mentioned in its patent filings.
While Moderna was not open about its extensive government support in patent filings, the company has been open about it with the press–for good reason: the fast-tracking of Moderna’s COVID-19 vaccine development has been justified in large part because of that extensive past government support. That support highlights the close work Moderna and US government agencies have conducted together over the years developing this vaccine technology for MERS. Might this development have been part of the DARPA research discussed in the Whitney Webb article?
Next, we highlight a Nature article from last month describing the existing collaboration between the NIAID’s Vaccine Research Center and Moderna on a different vaccine. Moderna simply shifted gears and started working on the COVID-19 vaccine: it’s been a US government/Moderna collaboration from the very beginning.
An aspect of Moderna’s vaccine development that is of concern is the fact that mRNA vaccines are inexpensive to produce, facilitating the production of large amounts of stock. This, in turn, IF it is announced before election day, might not only boost Trump’s popularity, but such a development could provide a foundation for an assault on mail-in voting.
The news out of Moderna’s trial could be worse. The extremely small size of this sample, however, is a matter of concern.
Noteworthy in that general context is the observation by Jonathan King (professor of molecular biology at MIT), that Pentagon research into the application of genetic engineering to biological warfare could be masked as vaccine research, which sounds “defensive.”
In FTR #1130, we noted the role of four-star general Gustave Perna in Trump’s “Operation Warp Speed,” instituted by General Mark Milley, Chairman of the Joint Chiefs of Staff.
Whether the program serves as cover for military research seems a reasonable question to ask, under the circumstances.
We conclude with a look at the past–a historical element of biological warfare that reflects on the present.
In past programs and posts, we have briefly noted that military and [ostensibly] civilian programs officially involved with “epidemic prevention” might conceal clandestine biological warfare applications designed to create epidemics.
The official distinction between “offensive” and “defensive” biological warfare research is academic.
In that context, one should note that the official title of Unit 731, the notorious Japanese biological warfare unit was “the Epidemic Prevention and Water Purification Department of the Kwantung Army.”
The Whitney Webb article–once again–figures into this analysis:
The DARPA research is ostensibly aimed at preventing pandemics but–very possibly–masking preparations for offensive biological warfare projects. ” . . . . Many of these recent research projects are related to DARPA’s Preventing Emerging Pathogenic Threats, or PREEMPT program, which was officially announced in April 2018. PREEMPT focuses specifically on animal reservoirs of disease, specifically bats, and DARPA even noted in its press release in the program that it ‘is aware of biosafety and biosecurity sensitivities that could arise’ due to the nature of the research. . . . In addition, while both DARPA’s PREEMPT program and the Pentagon’s open interest in bats as bioweapons were announced in 2018, the U.S. military — specifically the Department of Defense’s Cooperative Threat Reduction Program — began funding research involving bats and deadly pathogens, including the coronaviruses MERS and SARS, a year prior in 2017. . . .”
